文献速递产科母胎医学

自身免疫性风湿病与抗磷脂综合征妊娠中的母体心血管事件

Maternal cardiovascular events in autoimmune rheumatic diseases and antiphospholipid syndrome pregnancies.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-02-29

基于加利福尼亚州2005至2020年单胎分娩人群的回顾性队列研究显示,自身免疫性风湿病(ARD)和原发性抗磷脂综合征(APS)孕妇的急性心血管事件(CVE)风险分别约为无此类疾病参照组的4.1倍和14.7倍,静脉血栓栓塞是最常见类型,合并APS或狼疮肾炎的SLE患者风险进一步升高。

要点

  • ARD妊娠急性CVE发生率为2.0%(388/19,340),原发性APS为7.0%(540/7,758),参照组为0.4%(24,402/7,004,334)。
  • ARD和APS妊娠的CVE调整相对风险分别为4.1倍(95%CI 3.7–4.5)和14.7倍(95%CI 13.5–16.0)。
  • SLE合并APS或狼疮肾炎时CVE风险显著升高,aRR分别为18.1(95%CI 13.9–23.6)和12.7(95%CI 10.1–15.9)。

核心结论

  • ARD和APS妊娠的传统心血管危险因素更多,CVE风险分别约为参照组的4倍和15倍。
  • SLE合并APS(18.1倍)和狼疮肾炎(12.7倍)的CVE风险大幅升高,VTE是最常见的CVE类型。
  • ARD妊娠中任何急性CVE的院内死亡率为1.3%(5/388)。

研究设计与样本

  • 采用加利福尼亚2005至2020年单胎分娩人群的回顾性队列研究,通过出生证书与母体记录链接识别ARD和原发性APS妊娠。
  • ARD组19,340例,原发性APS组7,758例,参照组7,004,334例,比较孕期至产后6周内的急性CVE。
  • 使用泊松分布对数线性回归估计调整相对风险(aRR)及95%CI,并对中介因素进行因果中介分析。

主要发现

  • ARD组急性CVE发生率为2.0%(388/19,340),原发性APS组为7.0%(540/7,758),参照组为0.4%(24,402/7,004,334)。
  • 与参照组相比,ARD组CVE的aRR为4.1倍(95%CI 3.7–4.5),原发性APS组为14.7倍(95%CI 13.5–16.0)。
  • ARD组388例CVE中,VTE 164例(42%),心力衰竭或围产期心肌病96例(25%),心律失常92例(24%);原发性APS组540例CVE中VTE 453例(83%)。
  • SLE总体CVE发生率为3.1%(159/8,422),SLE合并APS为10.7%(55/513),SLE合并狼疮肾炎为8.5%(77/903)。
  • SLE患者CVE的aRR为6倍(95%CI 5.3–6.8),合并APS或狼疮肾炎时aRR分别为18.1(95%CI 13.9–23.6)和12.7(95%CI 10.1–15.9)。

关键数值与推荐

  • ARD妊娠中急性CVE的院内死亡率为1.3%(5/388)。
  • 中介分析显示,ARD妊娠CVE超额风险中11.2%由子痫前期介导,妊娠期糖尿病或妊娠期高血压介导的比例<0.5%。
  • ARD和APS妊娠的VTE及非VTE CVE风险均升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE:: Antiphospholipid syndrome (APS) and autoimmune rheumatic diseases (ARDs) are known to increase the risk for cardiovascular events (CVEs) in the general population., However, research in pregnancy is limited. We compared the occurrence of acute CVEs in pregnant women with and without ARDs or primary APS using a Californian population-based cohort. STUDY DESIGN:: This was a retrospective cohort study of pregnant individuals who delivered singleton infants in California between 2005 and 2020. Birth certificates were linked by the Study of Outcomes of Mothers and Infants to maternal records. The study was approved by institutional review boards of the State of California and the University of California San Diego. Pregnancies with ARDs were identified by ≥1 International Classification of Diseases (ICD) code for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), spondyloarthritis, Sjogren’s syndrome, and other ARDs (systemic sclerosis, inflammatory myositis, and vasculitides) in maternal hospital discharge, emergency, or ambulatory surgery records. Lupus nephritis (LN) was defined as SLE plus glomerulonephritis, renal failure, nephritic or nephrotic syndrome, or proteinuria. Primary APS included women with APS without concurrent ARDs. Women without ARDs or APS comprised the reference group. Acute CVEs during pregnancy and up to 6 weeks postpartum were identified by ICD codes and compared between groups. CVEs were classified as myocardial infarction, cardiovascular accident, heart failure and peripartum cardiomyopathy, inflammatory heart diseases, cardiac dysrhythmias, and venous thromboembolism (VTE). Covariates identified and adjusted for include age, race and ethnicity, insurance, education, prepregnancy body mass index, preexisting hypertension, diabetes, hyperlipidemia, depression, and substance use disorders. A log linear regression with a Poisson distribution was used to estimate the adjusted relative risks (aRRs) and 95% confidence intervals (CIs) for the associations of ARDs and APS with CVEs. Analyses were performed using Statistical Analysis Software (SAS), version 9.4 (SAS Institute, Cary, NC). Causal mediation analyses were performed for potential mediators, such as gestational diabetes, gestational hypertension, and preeclampsia. RESULTS:: Overall, 19,340 women had ARDs, 7758 had primary APS, and 7,004,334 had neither condition. The ARD and APS groups had more traditional cardiovascular risk factors. Acute CVEs were observed in 2.0% of ARD cases (388/19,340), 7.0% of primary APS cases (540/7,758), and 0.4% of reference group cases (24,402/7,004,334). The aRR for CVEs in the ARD and APS groups in comparison with the reference group was 4.1-fold (95% CI, 3.7–4.5) and 14.7-fold (95% CI, 13.5–16.0), respectively (Table). Of the 388 CVEs that occurred in women with ARDs, 164 (42%) were VTEs, 96 (25%) were heart failure or peripartum cardiomyopathy, and 92 (24%) were cardiac dysrhythmias. In primary APS cases, 453 of 540 (83%) CVEs were VTE. Acute CVEs occurred in 3.1% (159/8,422) of patients with overall SLE, in 10.7% (55/513) of patients with SLE with APS, and in 8.5% (77/903) of patients with SLE with LN (Table). The aRR for CVEs was 6-fold higher among those with SLE (95% CI, 5.3–6.8) and was notably increased with concurrent APS or LN, with aRRs of 18.1 (95% CI, 13.9–23.6) and 12.7 (95% CI, 10.1–15.9), respectively (Figure). The risks for both VTE and non-VTE CVEs was increased among pregnancies affected by ARD and APS (Figure). Five of 6 in-hospital deaths in ARD pregnancies (5/388 or 1.3%) occurred among women with acute CVEs (Table). The risks for CVEs were higher during all perinatal periods. In mediation analyses, 11.2% of the excess risk for CVE in ARD pregnancies was mediated by preeclampsia, whereas <0.5% was mediated by gestational diabetes or hypertension. CONCLUSION:: Pregnancies affected by ARDs and APS had both more traditional cardiovascular risk factors and about a 4-fold and 15-fold higher CVE risk, respectively, than the reference group. Pregnancies affected by SLE with APS (18.1-fold) and LN (12.7-fold) had substantial increased risks for CVEs. VTEs were the most frequently observed CVEs. The in-hospital mortality rate for any acute CVE in ARD pregnancies was 1.3% (Table).

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Dhital R, Baer RJ, Bandoli G, et al. Maternal cardiovascular events in autoimmune rheumatic diseases and antiphospholipid syndrome pregnancies. Am J Obstet Gynecol MFM. 2024. PMID: 38428526. doi:10.1016/j.ajogmf.2024.101319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。